Greater Glasgow and Clyde Medicines

Formulary Search Results for: FLUTICASONE FUROATE AND VILANTEROL

If the searched medicine is not listed in the NHSGGC Formulary, please check if the relevant therapeutic chapter is now available on the West of Scotland Formulary — visit formulary.nhs.scot/west.

12.2.1 Drugs used in nasal allergy - View Category

Total Formulary
Specialist and GP
FLUTICASONE FUROATE

Restrictions:

Restricted to specialist initiation. Restricted to allergic rhinitis patients in whom beclomethasone and budesonide have been ineffective or not tolerated.

BNF Link

12.2.1 Drugs used in nasal allergy - View Category

Total Formulary
Specialist and GP
FLUTICASONE PROPIONATE

Restrictions:

Restricted to specialist initiation where fluticasone nasal sprays should be reserved for patients in whom beclometasone and budesonide have been ineffective or not tolerated. Flixotide Nasules® are not included in the GGC Formulary.

BNF Link

12.2.1 Drugs used in nasal allergy - View Category

Total Formulary
MOMETASONE FUROATE (Nasal spray)

Prescribing Notes:

Mometasone nasal sprays should be reserved for patients for whom preferred list options have been ineffective or not tolerated.

BNF Link

13.4.6 Potent - View Category

Total Formulary
MOMETASONE FUROATE (ELOCON) (cream, ointment and scalp application)

13.4.6 Potent - View Category

Total Formulary
FLUTICASONE PROPIONATE (CUTIVATE) (CREAM AND OINTMENT)

12.2.1 Drugs used in nasal allergy - View Category

Total Formulary
AZELASTINE, FLUTICASONE (nasal spray)

Restrictions:

For use in patients who require both a nasal steroid and nasal antihistamine and where compliance is considered to be an issue.

Prescribing Notes:

Patient should have tried monotherapy with a nasal steroid for 6-12 weeks first with no benefit.

BNF Link

2.8.4 Reversal of anticoagulation - View Category

Total Formulary
Specialist Only
ANDEXANET ALFA (ONDEXXYA) (infusion)

Restrictions:

Restricted to use only on the advice of a Consultant Haematologist for the reversal of anticoagulation in adults treated with a direct factor Xa inhibitor where there is life-threatening or uncontrolled bleeding.  In addition, use should be in accordance with the local protocol (in development).

BNF Link